healthcare policy

  • |

    CMS’s Proposed PBM Rule Puts Payment Details on the Table

    ByPhil McCracken

    CMS proposed new Medicare Part D rules on October 16 aimed at making pharmacy benefit managers (PBMs) explain more of their compensation and contractual arrangements. The proposal raises a useful invoice question: who pays the PBM, and what service is that payment buying? In health care, the answer can arrive dressed as a spreadsheet wearing a fake mustache.

    More detail for plan sponsors

    Under the proposal, PBMs would provide annual reporting on their compensation and cost performance in Part D. CMS also proposes greater transparency around price guarantees and disclosure to plan sponsors of certain terms in agreements between PBMs and drug manufacturers. Those details could help sponsors assess what they are paying for and how the arrangement is performing.

    That information would not automatically become public. The proposal focuses on reporting and disclosures for plan sponsors, giving them more material to examine; it is not a promise that every contract term or payment detail will be posted for everyone to see. More paperwork in the hands of the people managing a plan may improve their ability to scrutinize an arrangement, but it does not guarantee what they will conclude or do with it.

    The proposal also addresses how PBMs are compensated, with limits tying certain compensation to the fair market value of services rather than to drug costs. The distinction matters: a fee linked to a drug’s price can create a different incentive from a fee tied to a defined service. CMS’s proposal aims to make the relationship easier to inspect. Its practical effect would depend on the final requirements and how plan sponsors use the information.

    Transparency is not a discount coupon

    CMS says the proposal implements provisions in the 2026 Consolidated Appropriations Act. The agency’s fact sheet describes reporting, price-guarantee transparency, manufacturer-agreement disclosures and compliance requirements. But a proposal is not a receipt showing that a patient’s next prescription will cost less. The proposed disclosures do not establish that premiums or out-of-pocket costs will fall. Better information may help plan sponsors evaluate contracts; whether that changes what patients pay remains an open question.

    That is the useful distinction for patients and taxpayers: the policy is aimed at making payment arrangements easier for plan sponsors to examine, not announcing a price cut. A sponsor getting a clearer view of compensation and contract terms is a step toward accountability. It is not the same as savings reaching the pharmacy counter. Follow the invoice, then check whether the benefit made it past the conference room.

    Still a proposal

    The Federal Register inspection copy schedules publication for October 20, 2026, and lists December 15, 2026, as the deadline for comments. The rule is proposed, not final or already in effect. For now, CMS has put additional PBM payment and contract information on the table for plan sponsors to examine. The next test is whether clearer paperwork produces better oversight—and whether any gains eventually reach the people paying for prescriptions.

  • |

    The Drug Pricing Rule Has a Lobbyist in the Back Seat

    ByPhil McCracken

    I look at Washington’s healthcare paperwork the way a diner waitress looks at a fake coupon: polite, tired, and already hunting for the fine print. CMS is considering a proposed Medicare rule that could treat certain fixed-combination drugs as the same qualifying single-source drug as an originator medicine for price negotiation. Patients may see one prescription. The policy question is whether Washington sees one product—or several convenient identities parked under the same hood.

    CMS issued the proposal June 12, set an August 17 comment deadline, and is expected to finalize it in fall 2026. That makes this less a chemistry quiz than a money-trail dispute. If a combination product remains legally separate from the medicine it combines, more revenue could remain outside the negotiation process. That is not proof anyone designed the product as an escape hatch. It is the practical question sitting on the counter while everyone argues about labels.

    Inside Health Policy reported that biologics manufacturers objected to CMS’s approach, arguing that separate FDA categories raise legal-authority and innovation concerns. Those are serious arguments, and agencies should not smuggle major policy changes through a filing cabinet labeled “technical clarification.” But the industry’s preferred separation also has a financial consequence: separate categories can mean separate treatment when Medicare decides what qualifies for negotiation.

    This is where the fine print starts wearing donor perfume. The public argument is about innovation, regulatory boundaries, and whether CMS has gone too far. The money question is simpler: who benefits if the category stays split? Manufacturers may preserve separate revenue streams from negotiated pricing, while patients and taxpayers are left to admire the elegance of the classification system from the payment window.

    At the pharmacy drive-through, nobody orders “one originator medicine with a regulatory garnish.” They get a prescription. In Washington, however, one prescription can be asked to produce two billing identities, two receipts, and two opportunities to keep the negotiated-price window closed. The rule is still proposed, the dispute is still active, and the invoice has not finished crawling out from under the lobbyist’s coat. But the public should know what this technical fight can decide: whether a medicine’s category serves patients—or protects the revenue attached to it.

    Sources

  • |

    The Drug-Price Mystery Has a Lobbying Budget

    ByPhil McCracken

    Patients receive a prescription bill written like a ransom note from an accountant, while the pharmaceutical industry’s Washington invoice arrives in plain English. Bloomberg Government reported that PhRMA spent $7.4 million lobbying in the second quarter of 2026, bringing its year-to-date total to $19.6 million. I have seen less money spent renovating an entire Capitol Hill office, although admittedly fewer people were trying to influence the rulebook.

    That spending does not, by itself, prove that lobbying caused any particular drug price or defeated any particular proposal. It does reveal something less mysterious: the trade group representing major pharmaceutical interests has a very clear budget for being present while everyone else debates why medicine costs so much. When an industry spends millions to participate in the policy conversation, “expertise” starts looking a lot like a reserved seat with better coffee.

    The timing is the whole money trail. Washington continued debating Medicare negotiation, most-favored-nation pricing, and other proposals aimed at lowering costs. Those are policy arguments, not settled outcomes, and they deserve scrutiny on their details. But patients are routinely told that drug pricing is too complex for ordinary people to understand, just as the people affected by the bill are asked to wait outside the room while well-funded representatives explain the machinery.

    That is the access economy in its natural habitat: the public gets a maze of rebates, formularies, negotiations, and carefully polished explanations; lobbyists get calendars, meetings, and a professional vocabulary for turning private interests into public homework. The pharmaceutical lobbying total reported by Bloomberg Government is not the entire industry’s spending, and it is not evidence of illegal conduct. It is simply a large, legible number attached to an argument that is often presented as impossibly complicated.

    So Washington keeps searching for the missing answer to drug prices. Meanwhile, the money trail has already found the billing department. Patients get the mystery, lobbyists get the appointment calendar, and taxpayers get another explanation for why reform remains under review.

    Sources

End of content

End of content